Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Knife River Q3 Earnings Fall, Revenue Rises; Trims 2026 Revenue Guidance

Knife River Q3 Earnings Fall, Revenue Rises; Trims 2026 Revenue Guidance

MT newswireMT newswire2026/11/03 12:20
08:20 AM EST, 11/03/2026 (MT Newswires) -- Knife River (KNF) reported Q3 net income Tuesday of $2.43 per diluted share, down from $2.52 a year earlier. Analysts polled by FactSet expected $2.58. Total revenue for the quarter ended Sept. 30 was $1.28 billion, compared with $1.20 billion a year earlier. Analysts expected $1.30 billion. For 2026, the company lowered its revenue guidance to $3.38 billion to $3.43 billion from $3.4 billion to $3.6 billion. Analysts expect $3.43 billion.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12